Genus (LSE:GNS) is bringing its gene-edited pigs closer to market one regulator at a time. The animal genetics group's PRRS-resistant pig (PRP), bred by its PIC porcine Business to resist porcine reproductive and respiratory syndrome, has been approved or cleared in a growing list of countries. On 10 September 2026, in its preliminary results for the year to 30 June 2026, the company said commercialisation was now beginning in certain Latin American countries.
The US, the market that matters most, is further back in the queue. The Food and Drug Administration approved the gene edit in April 2025, and Canada followed in January 2026. Genus has said that successful commercialisation in North America also requires approvals in key US pork export markets, particularly Mexico and Japan. It is also in talks with regulators in China.
In the meantime, the FTSE 250 company's core business has done the heavy lifting: adjusted profit before tax rose 35 per cent in 2026, and the board has announced a £60 million share buyback.
What Genus Does
Genus sells breeding stock and genetics to pig and cattle farmers around the world. Genus PIC supplies porcine genetics, earning much of its income from royalties linked to the productivity of customers' herds. Genus ABS supplies bovine genetics, including sexed semen, mainly to dairy farmers. Royalty-based Revenue gives the porcine arm a relatively recurring profile, although both divisions are exposed to farm Economics and agricultural cycles.
The PRRS-Resistant Pig Explained
PRRS is described by Genus as one of the most devastating diseases in global pig farming. The company has cited studies indicating infection more than doubles the need for antibiotics. PIC's approach uses gene editing to make pigs resistant to the virus, rather than relying on vaccines or biosecurity alone.
Regulatory progress so far, according to Genus announcements:
- Brazil, Colombia and the Dominican Republic issued positive determinations before the US decision, treating PRP like conventional pigs.
- The FDA approved the gene edit for the US food Supply on 30 April 2025. Chief executive Jorgen Kokke called it a major step towards US commercialisation.
- Canada approved the gene edit in January 2026.
- During the 2026 financial year, Genus also secured approvals or positive determinations in Argentina, Uruguay and Peru.
Mexico and Japan are critical because they are major buyers of US pork. Without clearance, US producers could face difficulties exporting meat from gene-edited animals, which is why Genus has linked North American launch to those approvals. It has not given a US launch date.
Genus also points to a consumer survey in its results, which found 94 per cent of consumers are open to buying pork from gene-edited pigs, with reduced antibiotic use the biggest motivator. As a company-commissioned survey, that finding should be read in context.
Spending and Partnerships
PRP costs rose 15 per cent to £11.6 million in 2026, reflecting what the company called pre-commercialisation activities. Net R&D spending across the group was £14.7 million.
China provides another angle. On 31 January 2026, Genus formed a porcine joint venture with Beijing Capital Agribusiness (BCA), transferring 51 per cent of PIC China in exchange for a 49 per cent stake, net cash proceeds of £97.7 million and board representation. The agreement includes a five-year commitment to collaborate on commercialising PRP. China's regulatory approval, however, has not been announced.
Results That Fund the Wait
For the year to 30 June 2026, revenue slipped 2 per cent to £658.1 million, largely reflecting the China deconsolidation. However, adjusted profit before tax jumped 35 per cent to £100.2 million, and adjusted Earnings Per Share rose 35 per cent to 110.3p. Statutory profit before tax was £310.5 million, boosted by a £204.1 million gain on the China transaction. In July the company had guided that profit would be moderately ahead of consensus.
Genus PIC's adjusted operating profit, including joint ventures, rose 17 per cent to £130.8 million, with adjusted Royalty revenue up 5 per cent to £196.9 million, total volumes up 12 per cent and growth in Asia and Latin America offsetting weakness in North America. Genus ABS lifted adjusted operating profit by 17 per cent to £22.9 million, helped by its Value Acceleration Programme.
Net Debt fell to £71.8 million from £228.2 million, reducing Leverage to 0.4 times. The full-year Dividend rose 10 per cent to 35.2p, with a final dividend of 24.0p, and the board announced a £60 million buyback to be carried out during the 2027 financial year.
Risks Along the Path
The central risk to the PRP story is regulatory timing. Approvals in Mexico, Japan and China are outside Genus's control, and delays would push back the US launch. Commercial success is also not guaranteed after approval: adoption depends on producers, processors, retailers and consumers accepting gene-edited pork, and on the pricing model PIC can secure.
The core business carries its own risks. Genus expects cyclical weakness in key agricultural markets in 2027, North American porcine trading has been soft, and lower dairy prices have weighed on ABS demand. Currency movements also affect reported results, as most earnings are generated outside the UK.
Milestones on the Horizon
For the 2027 financial year, Genus expects adjusted profit before tax in line with consensus, which it put at £87.0 million to £96.6 million. That is moderately higher than its normalised 2026 figure of £90.3 million, which excludes one-off items. The company's AGM, typically held in November, often comes with a trading update. Beyond that, the key triggers for the PRP will be announcements from regulators in Mexico, Japan and China, alongside the first evidence of commercial sales in Latin America.
Final Assessment
Genus has moved its gene-edited pig from the lab to a steadily expanding list of regulatory approvals, including the US and Canada. Early commercial activity is starting in Latin America, and a stronger balance sheet, rising dividend and buyback are backed by profitable core operations. But the biggest prize, the North American market, still hinges on approvals in export markets, and timing remains uncertain. Until then, PRP is a meaningful long-term option sitting on top of a cyclical agricultural genetics business.






Please wait processing your request...